ETH Zurich spinout Spirochem has raised cash to accelerate its sales activities and boost productivity.

Spirochem, a Switzerland-based biotechnology spinout of Swiss Federal Institute of Technology in Zurich (ETH Zurich), raised an undisclosed sum today from unnamed UK and Switzerland-based backers.

Founded in 2011, Spirochem is commercialising a drug design platform that enables the development of treatments boasting improved physico-chemical and pharmaco-kinetic properties.

The technology also means the spinout’s clients, which include biotech and pharmaceutical firms, can optimise their drug candidates at an accelerated rate. It was developed by a research group led by Erick…